Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362523 | 1.00 | MAOA (0.33) | MAOAMAOBLOXPARP1SOS1 | |
| SCHEMBL4644733 | 0.95 | MAOA (0.33) | MAOAMAOBLOXMEN1KMT2A | |
| Ethane SCHEMBL27539333 | 0.91 | NLRP3 (0.33) | MAOAMAOBLOXPARP1 | |
| SCHEMBL19679234 | 0.82 | BCL2L1 (0.47) | PARP1BCL2L1BADCES1MEN1 | |
| SCHEMBL30899242 | 0.77 | HTR2C (0.48) | — | |
| SCHEMBL31127815 | 0.77 | CHRNB4 (0.33) | PARP1 | |
| SCHEMBL8436954 | 0.77 | BCL2L1 (0.42) | PARP1BCL2L1BADCES1MEN1 | |
| SCHEMBL13619034 | 0.77 | SOS1 (0.31) | SOS1 | |
| SCHEMBL13451350 | 0.77 | PARP1 (0.33) | PARP1SOS1MEN1KMT2ATP53 | |
| SCHEMBL31011770 | 0.76 | CHRNB4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946476-B1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RES & TECH GMBH & CO (DE) | 2001-11-21 | — | — | EP | claimed |
| US-6159392-A | 5,7-difluoro-1,2,3,4-tetrahydronaphthalene derivatives and their use thereof in liquid crystal mixtures | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2000-12-12 | — | — | US | claimed |
| US-20260060960-A1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | OSPEDALE PEDIATRICO BAMBINO GESU (IT) | 2026-03-05 | — | — | US | disclosed |
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| WO-2016089208-A2 | SULFONAMIDE, SULFAMATE AND SULFAMIDE DERIVATIVES OF ANTI-CANCER AGENTS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC" (NL) | 2016-06-09 | — | — | WO | disclosed |
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER INC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| EP-0946476-B1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RES & TECH GMBH & CO (DE) | 2001-11-21 | — | — | EP | disclosed |
| EP-0946476-B1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RES & TECH GMBH & CO (DE) | 2001-11-21 | — | — | EP | disclosed |
| EP-0946476-B1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RES & TECH GMBH & CO (DE) | 2001-11-21 | — | — | EP | disclosed |
| US-6159392-A | 5,7-difluoro-1,2,3,4-tetrahydronaphthalene derivatives and their use thereof in liquid crystal mixtures | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2000-12-12 | — | — | US | disclosed |
| EP-0946476-A1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946476-A1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946476-A1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-10-06 | — | — | EP | disclosed |
| EP-0944570-A1 | 5,7-DIFLUORO-3,4-DIHYDRO-2H-NAPHTHALENE-1-ONE DERIVATIVES AND THE USE THEREOF IN LIQUID CRYSTAL MIXTURES | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998027045-A1 | 5,7-DIFLUORO-3,4-DIHYDRO-2H-NAPHTHALENE-1-ONE DERIVATIVES AND THE USE THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998027042-A1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998027042-A1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998027042-A1 | 5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES AND THEIR USE THEREOF IN LIQUID CRYSTAL MIXTURES | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | APP, PSEN1, BACE1 | MAOA 32/4885MAOB 29/4885LOX 3859/4885 |
| US-20260060960-A1 | GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA | BACE1, BACE2, PSENEN | MAOA 4555/4885MAOB 4490/4885LOX 3140/4885 |
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | MAOA 2826/4885MAOB 2361/4885LOX 2402/4885 |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | APP, PSEN1, BACE1 | MAOA 32/4885MAOB 29/4885LOX 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.